Biotec Pharmacon ASA | Income Statement
Fiscal year is January-December. All values NOK Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
22,108.00
33,026.00
53,280.00
71,904.00
66,686.00
66,769
Cost of Goods Sold (COGS) incl. D&A
21,838.00
28,296.00
39,568.00
60,723.00
60,023.00
69,263
Gross Income
270.00
4,730.00
13,712.00
11,181.00
6,663.00
2,494
SG&A Expense
30,435.00
34,023.00
32,402.00
35,056.00
34,533.00
17,722
EBIT
30,165.00
29,293.00
24,667.00
16,441.00
27,870.00
17,130
Unusual Expense
46.00
-
-
-
-
-
Non Operating Income/Expense
6,394.00
5,746.00
6,275.00
4,549.00
2,260.00
1,549
Pretax Income
22,889.00
21,992.00
17,292.00
20,389.00
24,803.00
13,828
Consolidated Net Income
22,889.00
21,992.00
17,292.00
20,389.00
24,803.00
13,828
Net Income
22,889.00
21,589.00
17,344.00
20,480.00
24,938.00
13,989
Net Income After Extraordinaries
22,889.00
21,589.00
17,344.00
20,480.00
24,938.00
13,989
Net Income Available to Common
22,889.00
21,589.00
17,344.00
20,480.00
24,938.00
13,989
EPS (Basic)
0.60
0.51
0.40
0.47
0.57
0.30
Basic Shares Outstanding
38,087.00
42,451.00
43,864.00
43,945.00
43,945.00
46,140
EPS (Diluted)
0.59
0.50
0.39
0.46
0.57
0.30
Diluted Shares Outstanding
38,901.00
43,265.00
44,520.00
44,903.00
43,945.00
46,140
EBITDA
27,859.00
26,829.00
21,740.00
14,529.00
25,892.00
14,858
Other Operating Expense
-
-
5,977.00
7,434.00
-
3,086
Non-Operating Interest Income
928.00
1,555.00
1,100.00
601.00
807.00
267
Minority Interest Expense
-
403.00
52.00
91.00
135.00
161
About Biotec Pharmacon ASA
View Profile
